NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025
Estimated value
£4.1bn
Awarded value
£986.3m
Suppliers
1
Lots
1
Published
29 Jul 2025
Description
NHS Framework Agreement for Branded Medicines - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 CM/PHR/24/5680/01 - NHS Framework Agreement for Branded Medicines - Tranche B for North of England and Midlands & East. Period of Framework Agreement: 01 September 2025 to 31 August 2027 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/24/5680/02 - NHS Framework Agreement for Branded Medicines - Eculizumab and Ravulizumab for London & SOFE. Period of Framework Agreement: 01 September 2025 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.
Scope
- Reference
- CF-3097700D0O000000rwimUAA
- Total value
- £4,108,145,000 excluding VAT
- Commercial tool
- Standalone contract
- Contract dates
- 31 Aug 2025 to 30 Aug 2027
- CPV classifications
- 33600000
- Particular suitability
- Small and medium-sized enterprises (SME)
Submission & procedure
- Submission deadline
- 07 Apr 2025, 12:00 pm
Award details
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
£986.3m
Award date
30 Jun 2025
Contract start
31 Aug 2025
Contract end
30 Aug 2027